MP9956:SFG.GD3synthase-2A-GD2synthase Citations (4)
Originally described in: An Optimized GD2-Targeting Retroviral Cassette for More Potent and Safer Cellular Therapy of Neuroblastoma and Other Cancers.Thomas S, Straathof K, Himoudi N, Anderson J, Pule M PLoS One. 2016 Mar 31;11(3):e0152196. doi: 10.1371/journal.pone.0152196. eCollection 2016. PubMed Journal
Articles Citing MP9956:SFG.GD3synthase-2A-GD2synthase
| Articles |
|---|
| GD2-directed CAR-T cells in combination with HGF-targeted neutralizing antibody (AMG102) prevent primary tumor growth and metastasis in Ewing sarcoma. Charan M, Dravid P, Cam M, Audino A, Gross AC, Arnold MA, Roberts RD, Cripe TP, Pertsemlidis A, Houghton PJ, Cam H. Int J Cancer. 2020 Jun 1;146(11):3184-3195. doi: 10.1002/ijc.32743. Epub 2019 Nov 6. PubMed |
| Intratumoral IL-12 delivery empowers CAR-T cell immunotherapy in a pre-clinical model of glioblastoma. Agliardi G, Liuzzi AR, Hotblack A, De Feo D, Nunez N, Stowe CL, Friebel E, Nannini F, Rindlisbacher L, Roberts TA, Ramasawmy R, Williams IP, Siow BM, Lythgoe MF, Kalber TL, Quezada SA, Pule MA, Tugues S, Straathof K, Becher B. Nat Commun. 2021 Jan 19;12(1):444. doi: 10.1038/s41467-020-20599-x. PubMed |
| Small extracellular vesicles induce resistance to anti-GD2 immunotherapy unveiling tipifarnib as an adjunct to neuroblastoma immunotherapy. Liu X, Wills CA, Chen L, Zhang J, Zhao Y, Zhou M, Sundstrom JM, Schell T, Spiegelman VS, Young MM, Wang HG. J Immunother Cancer. 2022 Apr;10(4). pii: jitc-2021-004399. doi: 10.1136/jitc-2021-004399. PubMed |
| IgA antibody immunotherapy targeting GD2 is effective in preclinical neuroblastoma models. Stip MC, Evers M, Nederend M, Chan C, Reiding KR, Damen MJ, Heck AJR, Koustoulidou S, Ramakers R, Krijger GC, de Roos R, Souteyrand E, Cornel AM, Dierselhuis MP, Jansen M, de Boer M, Valerius T, van Tetering G, Leusen JHW, Meyer-Wentrup F. J Immunother Cancer. 2023 Jul;11(7):e006948. doi: 10.1136/jitc-2023-006948. PubMed |
If you have published an article using this material, please email us at [email protected] to have your article added to this page.